Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | S100A4 | P26447 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27661302 | 0.90 | ALDH1A1 (0.40) | ALDH1A1TDP1KDM4ECYP1A2ABCB1 | |
| SCHEMBL6065335 | 0.89 | ALDH1A1 (0.49) | ALDH1A1TDP1KDM4ECYP1A2PDK1 | |
| SCHEMBL27732126 | 0.87 | KDM4E (0.40) | ALDH1A1TDP1KDM4ECYP1A2PDK1 | |
| SCHEMBL16390168 | 0.84 | ALDH1A1 (0.61) | ALDH1A1TDP1KDM4ECYP1A2MAPK1 | |
| SCHEMBL27956781 | 0.80 | HPD (0.48) | ALDH1A1MAPK1PKMRAB9AMEN1 | |
| SCHEMBL3007205 | 0.79 | CYP1A2 (0.50) | KDM4ECYP1A2PDK1ABCB1ABCC1 | |
| SCHEMBL29433438 | 0.79 | CYP1A2 (0.50) | KDM4ECYP1A2PDK1ABCB1ABCC1 | |
| SCHEMBL7421292 | 0.79 | MAOB (0.52) | ALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL18498886 | 0.78 | MAOB (0.40) | ALDH1A1TDP1KDM4ECYP1A2ABCB1 | |
| SCHEMBL25565309 | 0.78 | ALDH1A1 (0.51) | ALDH1A1TDP1KDM4EPDK1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101056632-B | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2011-12-07 | — | — | CN | disclosed |
| US-7879808-B2 | potent activity against resistant pneumococci; for treating domestic fowl | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
| EP-2151447-A1 | LINCOMYCIN DERIVATIVES AND ANTIBACTERIAL AGENTS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Meiji Seika Kaisha Ltd. (JP) | 2010-02-10 | — | — | EP | disclosed |
| CN-101522026-A | Protein kinase inhibitors and methods for using thereof | IRM LLC (VG) | 2009-09-02 | — | — | CN | disclosed |
| CN-1240677-C | Monofluoroalkyl derivatives | LILLY CO ELI (US) | 2006-02-08 | — | — | CN | disclosed |
| CN-1349497-A | Monofluoroalkyl derivatives | LILLY CO ELI (US) | 2002-05-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | LAS1L, LCLAT1, LYPLA1 | ALDH1A1 3224/4885TDP1 4210/4885KDM4E 3818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.